Mangoceuticals Overview
Latest ROE for Mangoceuticals: -142.53% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-142.53%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Mangoceuticals (MGRX) currently reports a ROE of -142.53%. That is below the sector sector average of -4.47%. Use the charts on this page to explore Mangoceuticals's ROE history and peer comparisons.
Mangoceuticals's ROE of -142.53% is lower than the its sector sector average of -4.47%. That is roughly 3089.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Mangoceuticals's current -142.53% should be judged against industry norms (sector average: -4.47%) and against MGRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -142.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for Mangoceuticals, and consider following MGRX for alerts when major investors trade the stock.
